Eflapegrastim

(Rolvedon®)

Rolvedon®

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (subcutaneous; 13.2 mg/0.6 mL)
Drug ClassLeukocyte growth factors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Eflapegrastim (Rolvedon) is used to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • A study focused on the effectiveness and safety of long-acting granulocyte colony-stimulating factors (LA-G-CSFs), including eflapegrastim, was reviewed.
  • The study indicates that a 13.2 mg dosage of eflapegrastim significantly outperforms other LA-G-CSFs in reducing the incidence of febrile neutropenia and severe neutropenia without introducing significant severe adverse events, thereby enhancing treatment efficacy without compromising safety.
  • At this higher dosage level, eflapegrastim does not result in a significant increase in severe adverse events when compared to other dosages or LA-G-CSFs, suggesting it offers a favorable safety profile for patient management during chemotherapy.
  • The benefits of this drug are specifically targeted towards adult patients with breast cancer undergoing myelosuppressive chemotherapy; however, the study did not provide detailed information about its effects on different population subgroups such as varying cancer types or pediatric populations.
  • When compared to other LA-G-CSF regimens like lipegfilgrastim and possibly others unspecified, eflapegrastim at 13.2 mg is one of the most effective options for managing chemotherapy-induced neutropenia among breast cancer patients due to its high efficacy rate coupled with minimal safety concerns.

Product Monograph / Prescribing Information

Document TitleYearSource
Rolvedon (eflapegrastim-xnst) prescribing information. 2022Spectrum Pharmaceuticals Inc., Irvine, CA

Systematic Reviews / Meta-Analyses